Randox Health Grand National Family Fun Day launched at The Cope
Randox Health Grand National Family Fun Day launched at The Cope
RTÉ Raidió na Gaeltachta show Barrscéalta, together with Randox Health, would like to invite the public to join them for a special live show from The Cope in Dungloe at 11 am on Friday 16th February, to launch the upcoming Randox Health Grand National Family Fun Day.
To celebrate their sponsorship of the Grand National, Randox Health has offered Barrscéalta a superb prize of a trip for two to the event, to include flights and accommodation, and entry to the Randox Health Grand National. Listeners can enter the competition by text in the week running up to the show from Dungloe – tune in to RnaG for full details – and all those who turn up for the live programme can also enter on the day to be in with a chance to win. The winner will be drawn during the show.
Dr Peter FitzGerald, Randox Managing Director, commented;
“We are delighted to offer this prize to one lucky listener, in recognition of the consistent support Randox Teoranta has received from the local community since our establishment in Donegal in 2008.”
“Our aim to offer world-leading science, engineering and software careers in west Donegal, so that people working in these fields no longer have to move away from home to find work, has been incredibly well-received. We’re therefore delighted that we’ll have representatives from Dungloe join us at the Randox Health Grand National as we celebrate together how far we have come.”
On Friday 16th February, there will also be lots of spot prizes for members of the audience, and plenty of tea, coffee and traybakes, supplied by The Cope. The brand new Randox Health Grand National trophy, which will be unveiled to the public for the first time on 13th February at the prestigious Weights Event in London, will be on display during the programme. The new trophy, designed and created by renowned Liverpool silversmith Shannon O’Neill, stands 45 cm high and is made of solid silver gilded with gold.
Speaking of the trophy, Dr FitzGerald said;
“There is no other race in the world like the Randox Health Grand National, and we want to ensure that the trophy reflects the status of the achievement.”
The Randox Health Grand National Family Day will take place in Randox Teoranta, Meenmore, on the 14th April from 1 pm – 6 pm. It’s a free event for all the family, with plenty of entertainment for kids, including a bouncy castle, as well as food and drink, live music and dance, craft stalls and a large screen for the public to watch the big races over at Aintree. RTÉ Raidió na Gaeltachta’s sports programme Spórt an tSathairn, presented by Seán Bán Breathnach, will be broadcasting live from the event on 14th April.
Áine Ní Churráin will present this special edition of Barrscéalta on RTÉ Raidió na Gaeltachta live from The Cope on Friday 16th February. All are welcome to attend the event which will take place between 11 am and 12 pm. There is no need to book.
For further information please contact the Randox PR Team: phone 028 9442 2413 or email randoxpr@randox.com
Drug and Alcohol Testing in the Medico-legal Market
Medico-legal testing for drugs and alcohol may be required by various professional bodies involved in child custody cases, care proceedings or child protection cases. In cases regarding divorce and children, a dispute may arise during the process of discussions involving the custody of children. In these cases drug and alcohol testing may be sought if there has been a substance abuse claim against a parent fighting for custody or visitation. In cases relating to child protection, social services may seek drug and alcohol testing if child welfare claims have been made regarding suspected substance misuse.
Normally in medico-legal cases a hair sample would be tested as it provides the longest detection window.
Why is Drug and Alcohol Testing in Medico-legal Cases Important?
Drug and alcohol testing is important to ensure child protection from the detrimental effects of parental substance misuse and to ensure they have a quality of life they deserve. In addition it is also important to enable parents the opportunity to get the help and support they need and begin rehabilitation treatment.
Doing the right thing by the child is the main priority, and where possible parent and child relationships are sought to be maintained. Drug and alcohol testing assists in these efforts and in such cases abstinence monitoring testing may be required to assess a parentās recovery e.g. if a visitation case is being reassessed.
Our Expertise
At Randox Testing Services we provide drug and alcohol testing to all professionals within the family law and medico-legal sector. Our hair drug testing service utilises accredited testing methods and is made more cost-effective through utilising patented testing methods developed by Randox.
We understand the impact a positive result can have on a parent, child, and extended family and ensure results of the highest precision and accuracy. With over 35 yearsā experience in the diagnostic industry we have gained reputation as a trusted provider.
Our drug and alcohol testing solutions are flexible and can be tailored to our customer needs with a choice of testing methods. We offer a comprehensive drugs of abuse test menu and our service also includes expert witness reporting where applicable.
Contact Us
To speak to one of our experts about hair drug testing contact enquiries@randoxtesting.com or call +44 (0) 161 741 2760. We work with companies within the medico-legal sector along with a wide range of workplaces and also private individuals.
For further information on RTS, or to arrange interviews, please contact the Randox PR team via email: randoxpr@randox.com or phone 028 9442 2413
Randox Laboratories and Qnostics announce strategic partnership
Randox Laboratories and Qnostics have today announced that they have entered into a strategic partnership. The partnership will provide Randox Laboratories with access to the Qnostics molecular range of products for sales and distribution purposes, complementing the established Randox Laboratories portfolio.
Access to the Randox Laboratories commercial capabilities will enhance Qnostics’ market penetration, whilst also maintaining their presence as an independent provider of molecular quality controls and custom services.
MD of Randox Laboratories, Dr Peter FitzGerald said;
“We are delighted to have agreed a strategic partnership with Qnostics, an arrangement we see as mutually beneficial. We look forward to working together to strengthen the molecular service we provide to our global markets whilst enhancing the Qnostic brand and market penetration.”
Dr Frank Opdam, Head of Commercial of Qnostics said;
“We believe this is an ideal partnership. We look forward to working with Randox Laboratories and the growth that will result from the global access this partnership will provide to Qnostics for its expanding range of molecular quality control products.”
For further information please contact the Randox PR Team: phone 028 9442 2413 or email randoxpr@randox.com
The Complete Solution to Cardiac Risk Assessment
“CVDs are the number 1 cause of death globally: more people die annually from CVDs than from any other cause”. In 2015, roughly 17.7 million people died from CVD, representing 31% of all global deaths: 7.4 million were due to coronary heart disease and 6.7 million were due to stroke. (WHO, 2017)
Cardiac health and regular cardiovascular screening is important to enable risk factors to be detected in their earliest stages. There are a few factors which contribute to CVD. These include: smoking, unhealthy diet, excessive alcohol consumption, low physical activity levels. Whilst there are only a few factors contributing to CVD, these can be maintained by the patient through living a healthy lifestyle including: quitting smoking, consuming no more than the recommended allowance of alcohol, cutting out junk food, and exercising for 30 minutes a day, 3 – 5 days a week. In a perfect world, this would be easy and CVD would not be a global problem. However, due to busy lifestyles, cravings, reduced willpower, and convenience, not all individuals in today’s world will be able to avoid CVDs. Therefore, it is vitally important that individuals are tested for CVDs to detect them in the earliest stages to reduce damage, prevent further damage, or even death. Furthermore, many individuals suffer from inherited cardiac risk factors, which stresses the need for accurate testing of both traditional and novel cardiac risk biomarkers.
Randox offer the complete solution to cardiac risk assessment including: RX analysers, traditional and novel reagents, internal quality control (Acusera), and external quality control (RIQAS).
RX Series
Randox has developed the RX series range of clinical chemistry analysers for high-quality semi-automated and fully automated testing. Choose between the RX misano, RX monaco, RX daytona+, RX imola, and the RX modena depending on the throughput of your laboratory. The RX series offers a suitable analyser for your laboratory’s needs. For more information on the Randox RX series, please click here or email therxseries@randox.com
Reagents
As previously mentioned, early assessment of cardiac risk is vital. Randox offer a range of novel risk biomarkers for both very early and the genetic assessment of cardiac risk.
LDL cholesterol is often referred to as the ‘bad cholesterol’. High concentrations of LDL-cholesterol is considered to be the most important clinical predictor, of all single parameters, with respect to coronary atherosclerosis. However, sLDL is a smaller, more dense subfraction of LDL-cholesterol. sLDL particles more readily permeate the inner arterial wall and are more susceptible to oxidation. Individuals with a predominance of sLDL have a 3-fold increased risk of myocardial infarction. Measurement of sLDL allows the clinician to get a more comprehensive picture of lipid risk factors and tailor treatment accordingly.
Elevated levels of Lp(a) are considered to be both a casual risk factor and independent genetic marker of atherosclerotic disorders. The major challenge associated with Lp(a) measurement is the size variation of apo(a) within Lp(a). Dependent upon the size of apo(a) in the assay calibrator, many assays under or overestimate apo(a) size in the patient sample. Numerous commercially available products suffer apo(a) size related bias, resulting in an over estimation of Lp(a) in samples with large apo(a)molecules and an under estimation in samples with small apo(a) molecules. The antibody used in the Randox method detects the complete Lp(a) molecule providing accurate and consistent results. This was proven by the IFCC who developed a gold standard ELISA reference assay and compared 22 commercially available tests. The Randox Lp(a) method displayed the least (minimal) amount of apo(a) size related bias, proving it be a superior offering.
HDL3 Cholesterol is a smaller and more dense subfraction of the HDL particle. HDL is the scavenger of cholesterol within arterial walls and the levels of HDL3 is too low, the ability to remove this cholesterol is reduced. Therefore, it is widely accepted that there is an inverse correlation between HDL3 and CVD risk.
Instrument Specific Applications (ISA’s) are available for a wide range of biochemistry analysers. Contact us to enquire about your specific analyser.
For more information on Randox Reagents, please click here or email reagents@randox.com
Acusera – Internal Quality Control
The Acusera cardiac controls have been designed to cover a wide range of cardiac markers at clinical decision levels, eliminating the extra expense of an additional low level control. The controls are available in a both liquid ready-to-use and lyophilized formats making them ideal for all situations and manufactured from 100% human serum a matrix similar to that of the patient is guaranteed. For more information on the Randox Acusera internal quality control, please click here or email acusera@randox.com
RIQAS – External Quality Control
The RIQAS Liquid Cardiac EQA programme is designed to monitor the performance of up to 9clinically significant cardiac markers including: CK-MB mass, D-dimer, Digoxin, homocysteine, hsCRP, myoglobin, NT proBNP, troponin I, and troponin T. RIQAS is ISO/IEC 17043 accredited and allows the registration of up to five instruments at no extra cost. All samples are 100% human serum and provided in a liquid ready-to-use format for enhanced convenience. Submit your results bi-weekly and view reports online via RIQAS.Net. For more information on RIQAS, the world’s largest international EQA scheme, please click here or email acusera@randox.com
For further information, please contact the Randox PR team via email: randoxpr@randox.com or phone 028 9442 2413
Simple health checks, sophisticated science at Randox Health
What is health care? When we think of caring for our health, we think of going to the doctor when we feel ill. The healthcare cycle weāre accustomed to is one where we wait for symptoms to present themselves and then we visit a doctor, hoping to be prescribed medication to limit our symptoms.
Is this really health care? Are we really caring for our bodies in the best way possible by waiting for illness to manifest itself? What if we could properly look after our bodies by taking action early to stop illness in its tracks?
The key to this is identifying indicators of pre-illness, and the technology that allows you to do this is now available directly to you through Randox Health.
After investing over Ā£220 million in the invention and production of revolutionary blood-science technology, a single Randox Health check will deliver a complete picture of your health ā as it is now and crucially how it is likely to develop in the future.
Randox Health has proven that signs of disease or irregularity can be caught at their earliest stage. This means that, with early action, some cases of illness can even be prevented altogether. Our health checks include, but are not limited to, cancer surveillance, fertility monitoring, heart health, nutrition, digestive and diabetes health.
In other words, from one health check, youāll receive up to 350 results and afterwards avail of expert advice from the Randox scientists or a Randox Health GP. Not only that, but a complete 12-month programme and repeat testing come as standard so you can have full confidence that you are really taking care of yourself.
Look out for our new āHealth Made Simpleā blogs beginning next week, where weāll be delving in to the sophisticated science and diagnostic tests that power each Randox Health check.
Youāll find out about our Everyman, Everywoman and our Signature health checks, as well as our Specialised testing options which focus on specific health issues.
Find out more and start your Randox Health journey today.
For further information, please contact the Randox PR team via email: randoxpr@randox.com or phone 028 9442 2413
The RX misano: a user-friendly analyser for honey quality testing
Honey naturally contains a small amount of enzymes which can vary widely by floral source and region. These enzymes play an important role by contributing to functional properties of honey, making it a unique ingredient that is far more complex than other sweeteners.
According to the EU Honey Directive 2001/110/EC, certain composition criteria must be determined for honeys intended for human consumption. In order to achieve this, the most modern enzymatic analyser in the industry, the RX misano, is now available for the analysis of diastase, total sugars (glucose/fructose), HMF and colouration.
Designed with the user in mind, the RX misano incorporates a responsive touch screen display, test menu personalisation and the ability to upload new parameters via USB. With an increase in automatic features, the RX misano also guarantees the precision and accuracy of results, improving the overall efficiency and versatility of enzymatic honey analysis.
The RX misano for honey suits a wide variety of users from bee keepers, to large honey producers/packagers and QA laboratories. It’s table top size allows it to be very versatile in different locations and needs very little maintenance from the user. The user-friendly interface and simple sample preparations means there is no need for the user to have had previous lab experience to run honey samples with the analyser.
For a summary of the benefits of the RX misano see below.
User friendly
7” responsive touch screen display, favourites menu, on screen prompts, the ability to export data into excel and import new menus.
Semi-automated
With the ability to automatically calculate results, the RX misano leaves less chance for human error.
Customisable test menus
As the RX misano for honey test menu continues to grow, users can simply upload new parameters to the machine via USB.
Accurate
Results are quantitative and produced within +/- 1% of UKAS accredited reference materials, boasting increased accuracy compared to alternative methods.
Reduced foot print
With a smaller footprint than standard spectrophotometers, the RX misano is suitable for laboratories of all sizes.
Excellent thermal performance
The RX misano heats to 37°C in less than 30 seconds and cools from 37°C to 25°C in less than 1 minute.
For more information on the RX misano or any of our other honey testing options please email us at: info@randoxfooddiagnostics.com.
GPs are told to stop prescribing antibiotics for sore throats
Today, the National Institute for Health and Care Excellence has published guidelines that state doctors should not prescribe precious antibiotics for most people with sore throats and should instead recommend drugs like paracetamol.
The guidelines from NICE and Public Health England, which aim to limit the use of antibiotics, said doctors should only be prescribing the medicines for more severe cases that are most likely to have been caused by a bacterial infection.
This is despite recent research that suggests antibiotics are prescribed in 60% of sore throat cases, for which doctors are unable to tell if the infection is viral or bacterial.
The National Institute for Health and Care Excellence said most sore throats were caused by viral infections, which cannot be treated by antibiotics.
At Randox, our pioneering R&D teams have developed a revolutionary swab test for respiratory infections which indicates the cause of the infection and whether a patient needs antibiotics or not. This helps to limit the number of patients who are prescribed antibiotics unnecessarily.
The Randox test, which can rapidly detect and identify the cause of 21 respiratory infections in just 5 hours, assists the clinician in prescribing the appropriate antibiotic.
John Lamont, Lead Scientist at Randox Laboratories, said;
“Current diagnostic testing for respiratory infections takes at least 36 hours to confirm the nature of an infection, and they cannot name and categorise infections as bacterial or viral in the way our new respiratory test can.”
This test, if widely adopted, could allow medical practitioners to make the correct treatment choice on the same day as examination and before patients have already begun a precautionary course of inefficient antibiotics. It would also have additional efficiency savings for the NHS, by eliminating the need for lengthy microbiology lab tests and unnecessarily prescribing drugs which are not needed.
This new rapid and accurate test will give clinicians confidence in their diagnosis of respiratory infections and will allow for quicker treatment if necessary, which benefits patient outcomes.
The test is also available as a Randox Health Cough, Cold & Flu offering, and can be carried out by booking an appointment with Randox Health at our clinics in Crumlin, Holywood or London, or by arranging the mobile clinic to visit you at your home or place of work.
Find out more about the Cough, Cold & Flu Respiratory test here.
Book an appointment with one of our clinics, or arrange the mobile clinic, by phoning 0800 2545 130 or by clicking here.
For further information please contact the Randox PR team by email: randoxpr@randox.com or phone 028 9442 2413
Evidence Investigator | Adaptable, Efficient & Comprehensive
The Evidence Investigator is a compact, semi-automated benchtop analyser that offers efficient and comprehensive testing across a range of applications including clinical diagnostics, molecular, research, toxicology and food diagnostics.
Renowned for its versatility, robustness and effective reporting methods, the Evidence Investigator has been used in a wide range of laboratory settings for over 15 years. This highly advanced yet simple to use analyser has only one moving part, giving the user peace of mind.
The Evidence Investigator contains a host of innovative on-board data analysis features ensuring manual processes are kept to a minimum.
By utilising the same multiplex technology as the other Evidence Series analysers, the Evidence Investigator can process up to 44 results from a single sample, with a maximum throughput of up to 2376 tests per hour. Offering efficiency without compromising on accuracy, the Evidence Investigator is the perfect fit for medium throughput laboratories seeking maximum use of bench space.
Accurate and Robust
Like all the Evidence Series analysers, what sets it apart is technology. The Evidence Investigator is extremely well equipped to provide reliable results, while simultaneously robust enough to withstand frequent, heavy use.
Results are generated using a Charge Coupled Device (CCD) camera, which quantifies chemiluminescent light. This light measures the degree of binding between the patient sample and specific biochip bound ligands, generating highly accurate and reliable results.
Consolidation
The Evidence Investigator is the world’s first platform allowing consolidation of immunoassay and molecular diagnostics. This is achieved through utilising protein and DNA based biochips. By giving the user the ability to consolidate tests, the Evidence Investigator improves laboratory efficiency and reduces costs.
Advanced Reporting
The Evidence Investigator image processing software translates light signal generated from chemiluminescent reactions into analyte concentration. This removes the need for any manual processing of data.
Previously unreported tests can also be retrieved, so they can be tested retrospectively. This saves time, labour costs and reduces any reagents wastage. All data is then analysed on-board, removing issues related to human error and result manipulation.
About the Randox Evidence Series
The Evidence Series is set to revolutionise diagnostic testing forever. Offering unrivalled capabilities across all analysers, we truly believe that the Evidence Series range of immunoassay analysers can meet your diagnostic testing capabilities.
For more information on the Evidence Investigator, or any of the Evidence Series analysers, visit https://www.randox.com/evidence-series/ or contact us evidenceseries@randox.com.
The Effect of Drug Deliveries and MDMA
A recent report by the Independent discussed how buying drugs has become as easy as buying ice cream. The report comes after experts named London as a city where cocaine is now delivered faster than pizza. According to the NHS, in the UK 2.7 million people between the ages of 16 and 59 took an illicit drug in 2015 and 2016 (roughly one in 12 adults). As a result, the Global Drug Survey are now looking at the impact of encrypted mobile phone messaging services and other methods that have enabled quick drug deliveries.
However, the drug problem is worldwide. In the US, life expectancy has fallen for the second consecutive year amid concerns of increased drug related deaths, the first multi-year drop since 1962 and 1963 according to the US National Centre for Health Statistics (NCHS). The NCHS documented that more than 63,600 US deaths in 2016 were due to drug related overdoses, a number that continues to increase.
MDMA has continued to appear in the news, after the deadly substance was responsible for the recent deaths of multiple teenagers in the UK. Also known as Ecstasy, MDMA is often described as the original designer drug due to its link with the dance culture in the late 80s and early 90s. Randox Toxicology’s DoA II panel tests for common drugs of abuse, including MDMA and generic opioids.
With the use of Biochip Array Technology, we have made multiplex testing capabilities possible. Our level of expertise in toxicology research and development allows us to adapt quickly to the ever-changing drug market influences and develop assays for current and novel drug trends.
| Analyte | Compound | Cross Reactivity % |
| MDMA | MDMA | 100 |
| MDEA | 321.7 | |
| PMMA | 23.75 | |
| MDA | 5.5 | |
| d,I,BDB | 4.8 |
Purity is a concern with MDMA, which is regularly sold containing other fatal drugs. Newshub released information from Wendy Allison at KnowYourStuffNZ, who stated that only 20 percent of the drugs they tested in New Zealand contained MDMA. KnowYourStuffNZ’s website advises people to avoid certain pressed pills containing large amounts of MDMA. Theses pills include “Green Guccis”, a rectangular green pill with the Gucci logo and “Yellow Rolexes”, a yellow pill shaped like the Rolex crown logo. The comedown of Ecstasy can cause users to feel depression, whilst long term users can suffer from memory problems and anxiety. The use of the Class A drug has also been linked to liver, kidney and heart problems.
For further information on our DoA II panel and how Randox Toxicology are advancing the future of toxicology, email info@randoxtoxicology.com
Molecular Diagnostics from Randox Biosciences
Our Randox Biosciences division is a trusted partner in supplying quality diagnostic solutions to the Clinical, Life Science, Pharmaceutical, Research and BioPharma industries.
Our molecular product range offers diagnostic, prognostic and predictive solutions across a variety of disease areas including sexually transmitted infections (STI), respiratory tract infection, colorectal cancer, familial hypercholesterolemia (FH) and cardiovascular disease (CVD).
Additionally, we can provide a wide range of assay formats including single nucleotide polymorphisms (SNP) genotyping, pathogen detection and mutation detection. The arrays are optimised for use with the Randox Evidence Investigator semi-automated, medium throughput bench-top biochip analyser.
One test, 10 results.
Our STI multiplex array II simultaneously detects 10 bacterial, viral and protozoan infections including primary, secondary and asymptomatic co-infections for a complete infection profile. The assay is based on a combination of multiplex, PCR and biochip array hybridisation. Innovative PCR priming technology permits high discrimination between multiple targets. A unique primer set is designed for each target which will hybridise to a complimentary oligo-nucleotide probe spotted on a biochip discrete test region (DTR).
The combination of priming and spatially organised biochip array technology enables enhanced specificity of the assay. Analysis can be completed from template DNA through PCR to data readout in less than 6 hours. The array is validated for urine and swab sample matrices with up to 53 patient samples being processed simultaneously. The array is CE marked for routine clinical use.
Our STI Multiplex Array II includes tests for the following STIs;
Neisseria Gonnorrhoea (NG) Mycoplasma Genitalium (MG)
Ureaplasma Urealyticum (UU) Chlamydia Trachhomatis (CT)
Tricomonas Vaginalis (TV) Haemophilus Ducreyi (HD)
Mycoplasma Hominis (MH) Treponema Pallidum (TP)
Herpes Simplex virus I (HSV-1) Herpes Simplex Virus 2 (HSV-2)
Randox Biosciences also offer four additional Molecular arrays.
For more information on our Molecular arrays please contact us by sending an email to Info@randoxbiosciences.com
